Nacimbio and Nanolec intend to combine their competencies and efforts in the development and organization of a full technological cycle for manufacturing immunobiological medicines at the facilities of both companies, including the technology transfer and joint research. The companies also plan to collaborate with the professional community in order to expand national and regional calendars of preventive vaccinations.
Nacimbio is open for cooperation and sharing the experience with leading pharmaceutical companies. We estimate that Nanolek has highly competent specialists in the area of vaccine manufacturing and great production capabilities; its technical equipment meets all requirements and high standards. The transfer of technology for manufacturing Sovigripp, a preventive vaccine against flu for children, to NANOLEC site in the Kirov region is scheduled by the end of 2018. “We are confident that cooperation with NANOLEC will have a synergistic effect for our companies and the Kirov region,” said Maryam Khubieva, CEO of Nacimbio.
Vladimir Khristenko, President of NANOLEC: “We see a number of promising opportunities in the partnership with Nacimbio, including the expansion of vaccine portfolio, which is our priority area; development of scientific and production capacity within the biotech cluster of Kirov region, as well as providing Russia with vaccines created with the most advanced technologies.”